Vertex Pharma

Forecast & Rating32 analysts currently cover Vertex Pharma, with about 81.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $571.39, about 13.0% upside from the current price of $505.64. Price targets range from $350.00 to $672.00 — a wide spread, showing clear disagreement over just how much Vertex Pharma can rise. Historically, about 99.5% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Vertex Pharma closely still see room for the stock to rise. Data as of Oct 7, 2026; for reference only and not investment advice.